Tikun Olam Cannbit Pharmaceuticals Ltd. Logo

Tikun Olam Cannbit Pharmaceuticals Ltd.

A vertically integrated pharma company developing research-backed, EU-GMP medical cannabis products.

TKUN | TA

Overview

Corporate Details

ISIN(s):
IL0010843675
LEI:
Country:
Israel
Address:
Ha'arbaa Street 21, 6473921 Tel Aviv-Yafo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tikun Olam Cannbit Pharmaceuticals Ltd. is a pioneering pharmaceutical company specializing in medical cannabis. The company operates a vertically integrated model, managing the entire value chain from genetics and cultivation to EU-GMP certified manufacturing and distribution. It focuses on developing stable, high-yielding proprietary strains with precise cannabinoid profiles to create standardized, accurately dosed products. A core differentiator is its commitment to research and development, substantiated by over 35 clinical studies and numerous scientific publications that validate the efficacy of cannabis for various medical conditions. The company also provides dedicated clinical nursing support to tens of thousands of patients, guiding their treatment and documenting outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-04-24 14:21
Regulatory News Service
Rights Offering and Identifying Details for New Security: TIKUN OLAM R5
Hebrew (modern) 182.1 KB
2022-08-17 17:30
Regulatory News Service
Opening of Trading On August 18 2022-TIKUN OL CN W3
Hebrew (modern) 107.6 KB
2022-07-26 15:47
Regulatory News Service
Rights Offering and Identifying Details for New Securities-Correction
Hebrew (modern) 185.9 KB
2022-07-26 15:04
Regulatory News Service
Rights Offering and Identifying Details for New Securities-TIKUN OL CAN R4, TIK…
Hebrew (modern) 314.1 KB
2021-05-30 18:08
Regulatory News Service
Tikun Olam-Cannbit – Rights Offering and Identifying Details for New Security
Hebrew (modern) 430.0 KB
2020-10-14 14:50
Regulatory News Service
Tikun Olam Canb – Rights Offering and Identifying Details for New Security
Hebrew (modern) 431.2 KB

Automate Your Workflow. Get a real-time feed of all Tikun Olam Cannbit Pharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tikun Olam Cannbit Pharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tikun Olam Cannbit Pharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden KLAR
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896

Talk to a Data Expert

Have a question? We'll get back to you promptly.